We spoke to Dr Federico Asch (MedStar Health Research Institute, Washington Hospital Center, Washington, DC, USA) about the World Alliance of Societies of Echocardiography (WASE) Normal Values Study, and the difficulties of applying these results worldwide. He discusses the racial and national differences in cardiac chamber size and function, and how this may affect routine practice.
Speaker’s Disclosures: Federico Asch has nothing to declare in relation to this video interview. The WASE study was sponsored by the American Society of Echocardiography, with in-kind donations from MedStar Health, the University of Chicago, TOMTEC and MEDIDATA.
1. What was the rationale for, and the results of, the World Alliance of Societies of Echocardiography (WASE) Normal Values Study? (0:04)
2. What were the most notable similarities and differences in cardiac chamber size and function between races and nationalities? (1:21)
3. How can these findings help physicians optimise management strategies for patients in routine practice? (2:21)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Society of Cardiology (ESC) Congress 2019 in Paris, France, September 2019.
Share this Video
Related Videos In Cardiovascular Disease
Michael Reardon, ACC 2022: Insights From the Corevalve US Pivotal and SURTAVI Trials: Five-year Incidence, Timing and Predictors of Hemodynamic Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses
Both the CoreValve US pivotal and SURTAVI trials investigated the five-year incidence, timing and predictors of haemodynamic valve deterioration of transcatheter aortic valve replacement (TAVR) surgery and surgical aortic bioprostheses in the treatment of severe, symptomatic aortic stenosis. Prof. Michael Reardon (Houston Methodist Hospital, Houston, TX) shares the insights and findings from these trials. Questions: […]
Milind Desai, ACC 2022: VALOR-HCM Trial
The VALOR-HCM trial showed the benefits of mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive hypertrophic cardiomyopathy. It was a pleasure to speak with Prof. Milind Desai (Cleveland Clinic, Cleveland, OH) about the VALOR-HCM trial including the efficacy and safety endpoints of it and what future […]
Milind Desai, ACC 2022: VALOR-HCM: Mavacamten as An Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy
An overview about the risks of surgical septal myectomy and alcohol ablation as treatments for obstructive hypertrophic cardiomyopathy and how mavacamten can provide an alternative was given by Prof. Milind Desai (Cleveland Clinic, Cleveland, OH). The presentation entitled ‘VALOR-HCM: Mavacamten as An Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients With Severely Symptomatic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!